Product Name: Human DLL3 Antibody (Rovalpituzumab, Research Use)
Catalog Number: NBR-0030
Target Name: DLL3
Trade Name: Rovalpituzumab
Antibody Drug Description: Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: DLL3
Synonyms: SCDO1
Target Description: DLL3 (Delta Like Canonical Notch Ligand 3) is a Protein Coding gene. Diseases associated with DLL3 include Spondylocostal Dysostosis 1, Autosomal Recessive and Spondylocostal Dysostosis, Autosomal Recessive. Among its related pathways are Gastrulation and Gene regulatory network modelling somitogenesis. Gene Ontology (GO) annotations related to this gene include calcium ion binding and Notch binding. An important paralog of this gene is DLK2.
Ensembl: ENSG00000090932
Uniprot: Q9NYJ7